A thalidomide-hydroxyurea hybrid increases HbF production in sickle cell mice and reduces the release of proinflammatory cytokines in cultured monocytes

• Compound 4C is a novel hydroxyurea-thalidomide hybrid designed to treat SCA.• Fetal hemoglobin production increased in sickle cell mice treated with compound 4C.• Production of proinflammatory cytokines by monocytes was reduced by compound 4C.

Source: Experimental Hematology - November 3, 2017 Category: Hematology Authors: Carolina Lanaro, Carla Franco-Penteado, Fabio H. Silva, Kleber Y. Fertrin, Jean Leandro dos Santos, Marlene Wade, Shobha Yerigenahally, Thais R. de Melo, Chung Man Chin, Abdullah Kutlar, Steffen E. Meiler, Fernando Ferreira Costa Tags: Brief Communications Source Type: research